Generation of membrane-permeable cyclic peptides inhibiting protein-protein interaction

  • Nat Chem Biol. 2026 Jun 1. doi: 10.1038/s41589-026-02237-7.
Xinjian Ji  #  1 ,  Lluc Farrera-Soler  #  1 ,  Jiajun Li  1 ,  Gontran Sangouard  1 ,  Nathan De Sadeleer  1 ,  Alexander L Nielsen  1 ,  Ganesh K Mothukuri  1 ,  Anne Zarda  1 ,  Edward J Will  1 ,  Florence Pojer  2 ,  Kelvin Lau  2 ,  Christian Heinis  3
Affiliations
  • 1. Institute of Chemical Sciences and Engineering, School of Basic Sciences, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.
  • 2. Protein Production and Structure Core Facility (PTPSP), School of Life Sciences, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.
  • 3. Institute of Chemical Sciences and Engineering, School of Basic Sciences, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland. [email protected].
  • # Contributed equally.
Abstract

Small, nonpolar cyclic Peptides can both bind challenging targets and cross cell membranes, making them attractive for addressing currently undruggable targets such as many protein-protein interactions (PPIs). However, developing such compounds de novo without prior information about lead structures such as natural ligands or fragments remains a notable challenge. Here we show that functional screening of structurally highly diverse cyclic peptide libraries synthesized at nanomole scale allows identification of sub-kDa inhibitors of a PPI. By screening 15,360 fully random cyclic Peptides, we were able to identify an inhibitor of the E3 Ligase adaptor KEAP1 and its substrate Nrf2. Optimization by rapid design-build-test cycles produced a membrane-permeable compound active in live cells. This study demonstrates that large, diverse cyclic peptide libraries can enable the discovery of cell-permeable PPI inhibitors from the ground up, providing a way to harness the powerful modality of small cyclic Peptides to address often difficult-to-target intracellular interactions.

Products